Omecamtiv Mecarbil Salt and Preparation Process

The United States Patent and Trademark Office (USPTO) has granted US Patent US12583821B2, titled 'Salt of omecamtiv mecarbil and process for preparing salt,' to Cytokinetics, Inc. The patent specifically covers omecamtiv mecarbil dihydrochloride salt forms, pharmaceutical compositions containing them, and methods for their preparation and use. This grant is related to organic chemistry (CPC classification C07D 213/75) and has applications in cardiovascular treatments (A61P 9/00, A61P 9/04, A61P 9/06).

This patent grant establishes intellectual property rights for Cytokinetics, Inc. regarding this specific salt form and its manufacturing process. For pharmaceutical companies involved in drug development, particularly in the cardiovascular space, this patent may affect their research, development, and commercialization strategies. While this is a patent grant and not a regulatory rule with compliance deadlines, it is crucial for entities operating in this therapeutic area to be aware of existing intellectual property rights to avoid infringement. The filing date for this application was January 24, 2024.